Vanderbilt Vaccine Research Program Archives
Dec. 16, 2020—The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.
Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.
Apr. 29, 2020—A preliminary look at data from hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) in a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir is showing promising results.
Jan. 28, 2019—Vanderbilt vaccine researchers are enrolling adult volunteers in a National Institutes of Health (NIH)-sponsored Phase II clinical trial that will study a next generation pertussis vaccine that may protect people from whooping cough.
Nov. 1, 2018—Vanderbilt researchers, as part of the International Human Vaccines Project, are searching for the key to lasting protection against influenza by examining naturally protecting cells found in bone marrow.
Oct. 26, 2017—Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world.
Jul. 13, 2017—New multicenter research that includes Vanderbilt University Medical Center (VUMC) investigators, could change treatment approaches to simple skin abscesses, infections often caused by Staphylococcus aureus (staph) bacteria.
Dec. 1, 2016—Researchers at Vanderbilt University Medical Center (VUMC) are leading a multicenter clinical trial to evaluate whether a shorter course of antibiotics — five days instead of 10 — is effective at treating community-acquired pneumonia (CAP) in children who show improvement after the first few days of taking antibiotics.